Pulmonary Disease, Chronic ObstructiveCOPDGeneNCT00608764
Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD)
An observational study of Pulmonary Disease, Chronic Obstructive and Emphysema, run by Brigham and Women's Hospital at 20 sites in United States.
Trial summary
Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that is often caused by cigarette smoking. The purpose of this study is to evaluate whether certain genetic factors predispose some smokers to develop COPD more than others. Read more about this study
- Who is it for?
- Ages 45 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Pulmonary Disease, Chronic Obstructive, Emphysema, Bronchitis, Chronic
- How many people
- 10,718 participants
- Where
- 20 sitesUnited States
- Study dates
- Nov 2007to Aug 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Particpants with COPD will include outpatient clinic patients, patients in registries, previous study participants, and COPD Foundation volunteers. Participants without COPD will include spouses and friends of study participants with COPD and patients at primary care practices.
Who may be able to join
- At least 10 pack-years of cigarette smoking (although a of nonsmoking controls is also being enrolled)
- Self-designation of non-Hispanic white or African-American
Who cannot join
- Other lung diseases (except for asthma in participants with COPD)
- Pregnant
- Cancer (other than skin cancer) in the 5 years prior to study entry
- Received antibiotics for a COPD exacerbation in the 1 month prior to study entry
- First- or second-degree relative of a previously enrolled study participant
Trial locations and contacts
20 sites in 1 country.
20 sites in 1 country
United States20 sites
Ann Arbor VA Medical Center
Ann Arbor, Michigan, 48105
University of Michigan
Ann Arbor, Michigan, 48109
Morehouse School of Medicine
Atlanta, Georgia, 30310
Johns Hopkins University
Baltimore, Maryland, 21224
University of Alabama at Birmingham
Birmingham, Alabama, 35249
Brigham and Women's Hospital
Boston, Massachusetts, 02115
National Jewish Health
Denver, Colorado, 80206
Duke University
Durham, North Carolina, 27710
Baylor College of Medicine
Houston, Texas, 77030
University of Iowa
Iowa City, Iowa, 52242
Minneapolis VA Medical Center
Minneapolis, Minnesota, 55417
HealthPartners Research Foundation
Minneapolis, Minnesota, 55440
University of Minnesota
Minneapolis, Minnesota, 55455
Columbia University Medical Center
New York, New York, 10032
Temple University
Philadelphia, Pennsylvania, 19140
University of Pittsburgh
Pittsburgh, Pennsylvania, 15232
University of Texas Health Sciences Center at San Antonio
San Antonio, Texas, 78229
University of California at San Diego
San Diego, California, 92103
Los Angeles Biomedical Research Institute
Torrance, California, 90502
Reliant Medical Group
Worcester, Massachusetts, 01608
About this study
Official title: Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (COPDGene)
Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that is often caused by cigarette smoking. The purpose of this study is to evaluate whether certain genetic factors predispose some smokers to develop COPD more than others.
Read the detailed description
COPD is a disease in which the lung airways are damaged and partly obstructed, making it difficult to breathe. Millions of people in the United States have COPD, and it is the third leading cause of death in the United States. Symptoms include coughing, excess mucus production, shortness of breath, wheezing, and chest tightness. Emphysema and long-term bronchitis are the two most common manifestations of the disease. The most common risk factor for developing COPD is cigarette smoking; however, only 15% to 20% of smokers develop COPD in their lifetimes. It is not known why some smokers develop COPD and some do not, but certain genetic factors, combined with exposure to cigarette smoke, may increase the likelihood of developing COPD. This study will analyze DNA from current and former cigarette smokers to identify genetic factors and markers that may indicate a predisposition to developing COPD.
This study will enroll African-American and white cigarette smokers and former cigarette smokers both with and without COPD. Participants will attend one study visit during which they will complete questionnaires about lung symptoms, breathing difficulties, medical and family history, and quality of life. They will also undergo blood collection, a physical exam, lung function testing, and a walking test to measure endurance. Participants will undergo a high resolution computed tomography (CT) chest scan and a medical record review. Study researchers will contact participants up to four times a year for 15 years to collect follow-up medical information. Five-year, ten-year, and fifteen-year follow-up visits including a similar study protocol as the baseline visit will be performed on all available subjects.
- Keywords
- Chronic Obstructive Pulmonary Disease, COPD, Emphysema, Chronic Bronchitis, Genetics, Association Studies, Computed Tomography
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive, Emphysema, Bronchitis, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| NHW COPD Participants | Non-Hispanic white participants with COPD | |
| NHW Control Group | Non-Hispanic white participants with normal spirometry (do not have COPD) | |
| AA COPD Participants | African-American participants with COPD | |
| AA Control Group | African-American participants with normal spirometry (do not have COPD) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Forced expiratory volume in 1 second (FEV1)
Measured: Measured at baseline
Emphysema, as shown on chest CT scan
Measured: Measured at baseline
Airway wall thickness on chest CT scan
Measured: Measured at baseline
COPD status (COPD participants versus control group participants)
Measured: Measured at baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Feb 2008 (estimated)
- Study startNov 2007
- Primary completionAug 2028 (estimated)
- Study completionAug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (127)Papers the sponsor has linked to this study.
- Other trials for Pulmonary Disease, Chronic ObstructiveStudies of the same condition, open and under way.
- More trials run by Brigham and Women's HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 10,718 participants (actual)
Sponsor and investigators
- Lead sponsor
- Brigham and Women's Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Responsible party
- Principal investigator, Edwin K. Silverman, Brigham and Women's Hospital
- Investigators
- James D. Crapo, MD, Principal investigator, National Jewish HealthEdwin K. Silverman, MD, PhD, Principal investigator, Brigham and Women's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00608764
- Sponsor's protocol ID
- 1428
- Other IDs
- 75N92023D00011-0-7, U01HL089856, U01HL089897
- Acronym
- COPDGene
- Status last verified
- Oct 2026
- First submitted
- 28 Jan 2008
- Last updated
- 21 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: COPDGene phenotypic and genotypic data are available through dbGaP.
Publications
Xanthavanij N, Deshpande R, Yu J, Marchetti N, Garshick E, Blanc PD, Regan EA, Crapo JD, Silverman EK, Wan ES. Occupational Exposure to Dust and Fumes Increases Risk for Future Adverse Clinical Outcomes. Am J Respir Crit Care Med. 2026 Jun 26:aamag334. doi: 10.1093/ajrccm/aamag334. Online ahead of print.
PubMed 42360751Curiale AH, Niethammer M, San Jose Estepar R. Prediction of Lobar Emphysema Progression with a CT-Based Foundational Model. Radiology. 2026 May;319(2):e252958. doi: 10.1148/radiol.252958.
PubMed 42188737Moore JM, Pratte KA, Ferguson C, Casaburi R, Iskander B, Abbasi A, Alapati P, Chilukuri S, Narashim A, Budoff MJ, Rossiter HB. High agreement of coronary artery calcification scores between full-dose (6.5 mSv) and reduced-dose (1.5 mSv) chest computed tomography: A retrospective analysis of COPDGene. J Cardiovasc Comput Tomogr. 2026 May 18:S1934-5925(26)00094-8. doi: 10.1016/j.jcct.2026.04.008. Online ahead of print.
PubMed 42150985Zeng S, Guo C, Pratte KA, Luo G, Bowler RP, Arjomandi M. Plasma proteomic profiles of lung volume-based phenotypes in tobacco-exposed individuals without spirometric chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2026 Jul 1;23(7):1033-1045. doi: 10.1093/annalsats/aaoag051.
PubMed 41776818Zhang C, Konigsberg IR, He Y, Zhang J, Chikowore T, Feldman WB, Hu X, Ding Y, Pasaniuc B, Chang D, Chen Q, Lasky-Su JA, Hecker J, Tobin MD, Chen J, Kalra S, Pratte KA, Im HK, Wan ES, Manichaikul A, Silverman EK, Bowler RP, Lange LA, Ortega VE, Martin AR, Cho MH, Moll MR. Multi-trait polygenic scores for COPD and COPD exacerbations implicate druggable proteins. JCI Insight. 2026 Feb 19;11(7):e199951. doi: 10.1172/jci.insight.199951. eCollection 2026 Apr 8.
PubMed 41712304Zhang C, Konigsberg IR, He Y, Zhang J, Chikowore T, Feldman WB, Hu X, Ding Y, Pasaniuc B, Chang D, Chen Q, Lasky-Su JA, Hecker J, Tobin MD, Chen J, Kalra S, Pratte KA, Im HK, Wan ES, Manichaikul A, Silverman EK, Bowler RP, Lange LA, Ortega VE, Martin AR, Cho MH, Moll MR. Multi-Trait Polygenic Scores for COPD and COPD Exacerbations Implicate Druggable Proteins. medRxiv [Preprint]. 2025 Aug 26:2025.08.22.25334001. doi: 10.1101/2025.08.22.25334001.
PubMed 40909810Phillips EK, Huang Y, Regan E, Make B, Strand M, Yohannes AM, Hanania NA, Bon J, Hoth KF, Crapo JD, Silverman EK, DeMeo DL. Frailty associates with respiratory exacerbations and mortality in the COPDGene cohort. Aging (Albany NY). 2025 Jul 3;17(7):1590-1623. doi: 10.18632/aging.206275. Epub 2025 Jul 3.
PubMed 40622758Awan HA, Chaudhary MFA, El-Sokkary AD, Hoffman EA, Comellas AP, Guo J, Barjaktarevic IZ, Barr RG, Bhatt SP, Bodduluri S, Bowler RP, Vargas Buonfiglio LG, Cooper CB, Fawzy A, Hastie AT, Labaki WW, Martinez FJ, Menchaca MG, O'Neal W, Paine R 3rd, Schroeder JD, Woodruff PG, Curtis JL, Reinhardt JM. Association of Lung Quantitative CT Scan Textures With Systemic Inflammation and Mortality in COPD. Chest. 2025 Nov;168(5):1107-1119. doi: 10.1016/j.chest.2025.04.017. Epub 2025 Apr 22.
PubMed 40268239Kalra S, Hobbs B, Hunninghake GM, Menon AA, Putman R, Cutting C, Hatabu H, Silverman EK, Wan E, Cho MH, Moll M. The Association of Interstitial Lung Abnormalities and Preserved Ratio Impaired Spirometry With Mortality. Chest. 2025 Jul;168(1):136-145. doi: 10.1016/j.chest.2025.02.002. Epub 2025 Feb 11.
PubMed 39947315Lee AN, Hsiao A, Hasenstab KA. Evaluating the Cumulative Benefit of Inspiratory CT, Expiratory CT, and Clinical Data for COPD Diagnosis and Staging through Deep Learning. Radiol Cardiothorac Imaging. 2024 Dec;6(6):e240005. doi: 10.1148/ryct.240005.
PubMed 39665633van der Veer T, Andrinopoulou ER, Braunstahl GJ, Charbonnier JP, Kim V, Latisenko R, Lynch DA, Tiddens H. Association between automatic AI-based quantification of airway-occlusive mucus plugs and all-cause mortality in patients with COPD. Thorax. 2025 Jan 17;80(2):105-108. doi: 10.1136/thorax-2024-221928.
PubMed 39638548Shirahata T, Enzer NA, Castro V, Chiles J, McDonald ML, Choi B, Diaz AA, Washko GR, San Jose Estepar R, Ash SY, Rahaghi FN. Effect of Common Medications on Longitudinal Pectoralis Muscle Area in Smokers. Chronic Obstr Pulm Dis. 2025 Jan 29;12(1):23-32. doi: 10.15326/jcopdf.2024.0557.
PubMed 39636057Bhatt SP, Nakhmani A, Sthanam V, Kizhakke Puliyakote A, Reinhardt JM, Bodduluri S. PiSlope: A New CT Metric for Quantifying Airway Remodeling in Chronic Obstructive Pulmonary Disease. Radiology. 2024 Nov;313(2):e240717. doi: 10.1148/radiol.240717.
PubMed 39589239Bell AJ, Ram S, Labaki WW, Murray S, Kazerooni EA, Galban S, Martinez FJ, Hatt CR, Wang JM, Ivanov V, McGettigan P, Khokhlovich E, Maiorino E, Suryadevara R, Boueiz A, Castaldi PJ, Mirkes EM, Zinovyev A, Gorban AN, Galban CJ, Han MK. Temporal Exploration of Chronic Obstructive Pulmonary Disease Phenotypes: Insights from the COPDGene and SPIROMICS Cohorts. Am J Respir Crit Care Med. 2025 Apr;211(4):569-576. doi: 10.1164/rccm.202401-0127OC.
PubMed 39269427Yang HM, Ryu MH, Carey VJ, Young K, Kinney GL, Dransfield MT, Wade RC, Wells JM, Budoff MJ, Castaldi PJ, Hersh CP, Silverman EK. Differential Association of COPD Subtypes With Cardiovascular Events and COPD Exacerbations. Chest. 2024 Dec;166(6):1360-1370. doi: 10.1016/j.chest.2024.07.148. Epub 2024 Jul 31.
PubMed 39094733
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (COPDGene)
- ClinicalTrials.gov ID
- NCT00608764
- Acronym / sponsor ID
- COPDGene / 1428
- Keywords
- Chronic Obstructive Pulmonary Disease, COPD, Emphysema, Chronic Bronchitis, Genetics, Association Studies, Computed Tomography
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 10,718 participants (actual)
- Lead sponsor
- Brigham and Women's HospitalUniversity, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Study start
- Nov 2007 (actual)
- Primary completion
- Aug 2028 (estimated)
- Study completion
- Aug 2028 (estimated)
- First posted
- 6 Feb 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that is often caused by cigarette smoking. The purpose of this study is to evaluate whether certain genetic factors predispose some smokers to develop COPD more than others.
Detailed description
COPD is a disease in which the lung airways are damaged and partly obstructed, making it difficult to breathe. Millions of people in the United States have COPD, and it is the third leading cause of death in the United States. Symptoms include coughing, excess mucus production, shortness of breath, wheezing, and chest tightness. Emphysema and long-term bronchitis are the two most common manifestations of the disease. The most common risk factor for developing COPD is cigarette smoking; however, only 15% to 20% of smokers develop COPD in their lifetimes. It is not known why some smokers develop COPD and some do not, but certain genetic factors, combined with exposure to cigarette smoke, may increase the likelihood of developing COPD. This study will analyze DNA from current and former cigarette smokers to identify genetic factors and markers that may indicate a predisposition to developing COPD.
This study will enroll African-American and white cigarette smokers and former cigarette smokers both with and without COPD. Participants will attend one study visit during which they will complete questionnaires about lung symptoms, breathing difficulties, medical and family history, and quality of life. They will also undergo blood collection, a physical exam, lung function testing, and a walking test to measure endurance. Participants will undergo a high resolution computed tomography (CT) chest scan and a medical record review. Study researchers will contact participants up to four times a year for 15 years to collect follow-up medical information. Five-year, ten-year, and fifteen-year follow-up visits including a similar study protocol as the baseline visit will be performed on all available subjects.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| NHW COPD Participants | – | –Non-Hispanic white participants with COPD |
| NHW Control Group | – | –Non-Hispanic white participants with normal spirometry (do not have COPD) |
| AA COPD Participants | – | –African-American participants with COPD |
| AA Control Group | – | –African-American participants with normal spirometry (do not have COPD) |
Who may qualify
- Ages
- 45 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Particpants with COPD will include outpatient clinic patients, patients in registries, previous study participants, and COPD Foundation volunteers. Participants without COPD will include spouses and friends of study participants with COPD and patients at primary care practices.
Key inclusion criteria (2 listed)
- At least 10 pack-years of cigarette smoking (although a of nonsmoking controls is also being enrolled)
- Self-designation of non-Hispanic white or African-American
Key exclusion criteria (5 listed)
- Other lung diseases (except for asthma in participants with COPD)
- Pregnant
- Cancer (other than skin cancer) in the 5 years prior to study entry
- Received antibiotics for a COPD exacerbation in the 1 month prior to study entry
- First- or second-degree relative of a previously enrolled study participant
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Forced expiratory volume in 1 second (FEV1)
Time frame: Measured at baseline
Emphysema, as shown on chest CT scan
Time frame: Measured at baseline
Airway wall thickness on chest CT scan
Time frame: Measured at baseline
COPD status (COPD participants versus control group participants)
Time frame: Measured at baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2026.
- Derived from this study: PubMed 42360751Xanthavanij N, Deshpande R, Yu J, Marchetti N, Garshick E, Blanc PD, Regan EA, Crapo JD, Silverman EK, Wan ES. Occupational Exposure to Dust and Fumes Increases Risk for Future Adverse Clinical Outcomes. Am J Respir Crit Care Med. 2026 Jun 26:aamag334. doi: 10.1093/ajrccm/aamag334. Online ahead of print.
- Derived from this study: PubMed 42188737Curiale AH, Niethammer M, San Jose Estepar R. Prediction of Lobar Emphysema Progression with a CT-Based Foundational Model. Radiology. 2026 May;319(2):e252958. doi: 10.1148/radiol.252958.
- Derived from this study: PubMed 42150985Moore JM, Pratte KA, Ferguson C, Casaburi R, Iskander B, Abbasi A, Alapati P, Chilukuri S, Narashim A, Budoff MJ, Rossiter HB. High agreement of coronary artery calcification scores between full-dose (6.5 mSv) and reduced-dose (1.5 mSv) chest computed tomography: A retrospective analysis of COPDGene. J Cardiovasc Comput Tomogr. 2026 May 18:S1934-5925(26)00094-8. doi: 10.1016/j.jcct.2026.04.008. Online ahead of print.
- Derived from this study: PubMed 41776818Zeng S, Guo C, Pratte KA, Luo G, Bowler RP, Arjomandi M. Plasma proteomic profiles of lung volume-based phenotypes in tobacco-exposed individuals without spirometric chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2026 Jul 1;23(7):1033-1045. doi: 10.1093/annalsats/aaoag051.
- Derived from this study: PubMed 41712304Zhang C, Konigsberg IR, He Y, Zhang J, Chikowore T, Feldman WB, Hu X, Ding Y, Pasaniuc B, Chang D, Chen Q, Lasky-Su JA, Hecker J, Tobin MD, Chen J, Kalra S, Pratte KA, Im HK, Wan ES, Manichaikul A, Silverman EK, Bowler RP, Lange LA, Ortega VE, Martin AR, Cho MH, Moll MR. Multi-trait polygenic scores for COPD and COPD exacerbations implicate druggable proteins. JCI Insight. 2026 Feb 19;11(7):e199951. doi: 10.1172/jci.insight.199951. eCollection 2026 Apr 8.
- Derived from this study: PubMed 40909810Zhang C, Konigsberg IR, He Y, Zhang J, Chikowore T, Feldman WB, Hu X, Ding Y, Pasaniuc B, Chang D, Chen Q, Lasky-Su JA, Hecker J, Tobin MD, Chen J, Kalra S, Pratte KA, Im HK, Wan ES, Manichaikul A, Silverman EK, Bowler RP, Lange LA, Ortega VE, Martin AR, Cho MH, Moll MR. Multi-Trait Polygenic Scores for COPD and COPD Exacerbations Implicate Druggable Proteins. medRxiv [Preprint]. 2025 Aug 26:2025.08.22.25334001. doi: 10.1101/2025.08.22.25334001.
- Derived from this study: PubMed 40622758Phillips EK, Huang Y, Regan E, Make B, Strand M, Yohannes AM, Hanania NA, Bon J, Hoth KF, Crapo JD, Silverman EK, DeMeo DL. Frailty associates with respiratory exacerbations and mortality in the COPDGene cohort. Aging (Albany NY). 2025 Jul 3;17(7):1590-1623. doi: 10.18632/aging.206275. Epub 2025 Jul 3.
- Derived from this study: PubMed 40268239Awan HA, Chaudhary MFA, El-Sokkary AD, Hoffman EA, Comellas AP, Guo J, Barjaktarevic IZ, Barr RG, Bhatt SP, Bodduluri S, Bowler RP, Vargas Buonfiglio LG, Cooper CB, Fawzy A, Hastie AT, Labaki WW, Martinez FJ, Menchaca MG, O'Neal W, Paine R 3rd, Schroeder JD, Woodruff PG, Curtis JL, Reinhardt JM. Association of Lung Quantitative CT Scan Textures With Systemic Inflammation and Mortality in COPD. Chest. 2025 Nov;168(5):1107-1119. doi: 10.1016/j.chest.2025.04.017. Epub 2025 Apr 22.
- Derived from this study: PubMed 39947315Kalra S, Hobbs B, Hunninghake GM, Menon AA, Putman R, Cutting C, Hatabu H, Silverman EK, Wan E, Cho MH, Moll M. The Association of Interstitial Lung Abnormalities and Preserved Ratio Impaired Spirometry With Mortality. Chest. 2025 Jul;168(1):136-145. doi: 10.1016/j.chest.2025.02.002. Epub 2025 Feb 11.
- Derived from this study: PubMed 39665633Lee AN, Hsiao A, Hasenstab KA. Evaluating the Cumulative Benefit of Inspiratory CT, Expiratory CT, and Clinical Data for COPD Diagnosis and Staging through Deep Learning. Radiol Cardiothorac Imaging. 2024 Dec;6(6):e240005. doi: 10.1148/ryct.240005.
- Derived from this study: PubMed 39638548van der Veer T, Andrinopoulou ER, Braunstahl GJ, Charbonnier JP, Kim V, Latisenko R, Lynch DA, Tiddens H. Association between automatic AI-based quantification of airway-occlusive mucus plugs and all-cause mortality in patients with COPD. Thorax. 2025 Jan 17;80(2):105-108. doi: 10.1136/thorax-2024-221928.
- Derived from this study: PubMed 39636057Shirahata T, Enzer NA, Castro V, Chiles J, McDonald ML, Choi B, Diaz AA, Washko GR, San Jose Estepar R, Ash SY, Rahaghi FN. Effect of Common Medications on Longitudinal Pectoralis Muscle Area in Smokers. Chronic Obstr Pulm Dis. 2025 Jan 29;12(1):23-32. doi: 10.15326/jcopdf.2024.0557.
- Individual participant dataSharing planned: Yes. COPDGene phenotypic and genotypic data are available through dbGaP.
Related trials for Pulmonary Disease, Chronic Obstructive
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Chronic Graft Versus Host Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
James D. Crapo, MD principal investigator
National Jewish Health
Edwin K. Silverman, MD, PhD principal investigator
Brigham and Women's Hospital
20 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pulmonary Disease, Chronic Obstructive and Emphysema, run by Brigham and Women's Hospital at 20 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 20 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Forced expiratory volume in 1 second (FEV1) (time frame: Measured at baseline). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00608764, which also lists 127 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.